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was developed and administered with the support of the main Italian OAT patients’ 
association. Returned questionnaires were checked for consistence and valid data were 
summarised. Travelling costs and earning losses were evaluated according to published 
prices. RESULTS: A total of 4722 valid questionnaires were returned from all over 
Italy. The prevalent OAT management model in this sample relies on hospital-based 
anticoagulation clinics. Patients incur signiﬁcant transportation, earning loss, and 
other out-of pocket costs at an estimated mean overall monthly cost of about a30. 
The distribution of costs in the population is wide, and depends mainly on monitoring 
frequency, home-clinic distance, and employment status. CONCLUSIONS: This study 
contributes to clarify the organisational models of the Italian OAT population and 
delivers data on patients’ costs that may be used when evaluating alternative manage-
ment options.
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OBJECTIVES: The Hellenic Society for Pharmacoecnomics and Outcomes Research 
(HELSPOR) assessed the effectiveness of recent policy reforms on controlling phar-
maceutical expenditure in Greece. METHODS: The latest available data on pharma-
ceutical expenditure in Greece derived from the National Statistical Service (NSS) were 
analyzed for the period of 2000–2007. RESULTS: Pricing and reimbursement systems 
implemented in Greece have been based on cost-containment rather than economic 
evaluation criteria. Cost containment policies introduced in the past (positive reim-
bursement list, pricing at the lowest EU price) had limited or no effect. In 2006, the 
reimbursement list was abolished and currently all marketed prescription medicines 
are reimbursed by Social Insurance. This, however, does not appear to be a sustainable 
system, as Insurance Funds exhibit signiﬁcant deﬁcits and hospitals incur enormous 
debts (in December 2008, hospital debt towards pharmaceutical companies was a2.66 
billion, exhibiting a remarkable increase within a year (38.3%)). Although two laws 
have been voted to introduce a reimbursement system that would replace the positive 
list, none has yet been implemented. The outcome of the past and current pharmaceuti-
cal policies in Greece has been the increase of pharmaceutical expenditure. Pharma-
ceutical expenditure rose to a 4.5 billion in 2007, accounting for 21.6% of total health 
care expenditure and 2% of GDP. Pharmaceutical expenditure increased over the 
period 2000–2007 at a mean annual growth rate (MAGR) of 13.4%, a rate higher 
than total health care expenditure (10.3%). CONCLUSIONS: Pharmaceutical policy 
reforms have increased expenses for Insurance Funds and hospitals. Implementation 
of economic evaluation criteria could be a start for rational decision making and cost 
containment in the pharmaceutical sector.
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OBJECTIVES: Despite the availability of Hungarian methodological guidelines the 
quality of economic evaluations submitted in pharmaceutical reimbursement dossiers 
are rather heterogeneous. The 10–12 point international critical appraisal checklists 
are not detailed enough to ﬁlter the problems occurring in Hungarian studies, therefore 
they are not widely used. As a consequence only small proportion of economic evalu-
ations are published in medical journals, which limits the development of health eco-
nomic skills and the broad utilisation of economic rationale in medical decision-making. 
The aim of our study was to develop a relevant Hungarian checklist for the critical 
appraisal of economic evaluations. METHODS: Fifty economic evaluations submitted 
for reimbursement of pharmaceuticals in 2007–8 were scrutinized by two independent 
reviewers to identify the most common methodological problems. Reviewers had no 
intention to revise previous reimbursement decisions. Based upon the assessment of 
10 studies, a draft checklist was developed. After assessing 25 reports, an extended 
workshop was settled to reconcile the opinion of reviewers and to improve the check-
list. The reviewers scrutinized the second 25 economic evaluations according to the 
checklist. The checklist was ﬁnalized at a second workshop. RESULTS: The ﬁnal 
checklist consists of 3–8 dichotomised questions in several major topics concerning 
comparator selection, effectiveness, costs, sensitivity analysis, methodological 
approach and interpretation of results. When the checklist is used for critical appraisal, 
reviewers may exclude non-relevant question items. CONCLUSIONS: Our checklist 
is based on current Hungarian practice. As the published checklist will be ofﬁcially 
used for the appraisal of economic evaluations in reimbursement dossiers, submitters 
can assure the quality of their economic evaluations and predict outcomes of the 
health technology assessment process. The transparent method of single technology 
assessment may improve the consistency of pharmaceutical reimbursement decisions 
and the utilization of economic evaluations in other ﬁelds of health care 
decision-making.
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OBJECTIVES: To determine whether there is a relationship between pharmaceutical 
consumption and health care results. This issue is of highest importance in the French 
political debate, France being one of the countries in Europe with the highest phar-
maceutical consumption and related expenses. METHODS: The levels of health care 
status of seven European countries (France, Denmark, Germany, Italy, Spain, Sweden 
and the UK) are compared through a range of indicators coming from sources (OECD, 
Eurostat, WHO) or scientiﬁc publications and systematically analyzed in comparison 
with health care and pharmaceutical expenses in each country. The analysis ﬁrst relies 
on global health care indicators such as life expectancy, life expectancy without dis-
ability and mortality rates by causes. A focus is then made on the two major causes 
of death in Europe: cancer and cardiovascular diseases. Analysis is conducted on 2004 
data. RESULTS: The highest life expectancy at 65, both for men and women, is posi-
tively correlated with the level of pharmaceutical consumption and expenses. Several 
studies (OMS) have suggested the high level of performance of the French health care 
system. The rather low level of life expectancy at birth for men is mostly the results 
of high mortality rates for external causes (suicides, injuries), independent from the 
health care system. Low mortality rates for cardiovascular diseases are associated with 
good management of risk factors through pharmaceutical treatments (hypolipidemic 
drugs). Regarding cancer, good results in terms of survival rates at ﬁve years are 
associated with a level of drug consumption high in value but more moderate in 
volume, this suggesting the use of innovating products. CONCLUSIONS: While it is 
not possible to demonstrate a ﬁrm cause-to-effect relationship between the relatively 
high investment in health care and the relatively better health care status in France 
compared with its European neighbours, a range of facts and ﬁgures do converge in 
support of this hypothesis.
PHP12
SHORTAGES IN THE AMERICAN MEDICAL DRUG MARKET
Stino M, McGhan WF
University of the Sciences in Philadelphia, Philadelphia, PA, USA
OBJECTIVES: The purpose of this study was to characterize the drugs in short supply 
in the American market on or before June 1, 2009 and to determine if certain char-
acteristics affect the duration of drug shortages. METHODS: We examined if the US 
Food and Drug Administration’s policy of identifying which drugs in short supply are 
“medically necessary” is effective in reducing the length of those shortages and if the 
market concentration (the number of manufacturers) of a drug is associated with the 
length of its shortage. Medical drug shortages create disruptions for buyers such as 
hospitals and pharmacies. They can affect public health, especially when the drug has 
few or no alternatives and can be considered medically necessary. We compiled pub-
licly-available data from the American Society of Health-Systems Pharmacists (ASHP) 
and the Food and Drug Administration (FDA) to determine the lengths of shortages, 
whether each drug had been deemed “medically necessary” by the FDA, and the 
number of active or defunct manufacturers for each drug. Using that data, we per-
formed statistical analyses to test two null hypotheses: 1) that there is no association 
between a drug in short supply being labeled “medically necessary” by the FDA and 
the length of its shortage; and 2) that there is no association between the number of 
manufacturers for a drug in short supply and the length of its shortage. RESULTS: 
We failed to reject our null hypotheses for both active shortages and resolved shortage 
drugs as listed by the ASHP on June 1, 2009. CONCLUSIONS: These results suggest 
that the FDA’s policy of determining which in-shortage drugs are “medically neces-
sary” did not reduce the duration of those shortages. The ﬁndings also indicate the 
number of manufacturers for a particular drug or device in short supply is not associ-
ated with the length of its shortage.
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OBJECTIVES: On the 1st of May 2004 Hungary—together with many European 
countries—joined to the European Union which resulted in several changes in the 
Hungarian legislation. In the coverage policy of pharmaceuticals, the Directive 89/105/
EEC of the Council of the European Communities on Transparency was implemented 
Hungary in order to provide regulation on decision on drug prices. The aim of our 
study is to calculate the average delay of decision-making on pharmaceutical reim-
bursement. METHODS: The data derive from the drug reimbursement database of 
the National Health Insurance Fund Administration (OEP) of Hungary covering the 
4 year period of 2005–2008. We calculated the delay as the time between the submis-
sion of application by the manufacturer and the ﬁrst day of reimbursement of drug. 
Our analysis covered drugs submitted within the frame of simpliﬁed procedure, drugs 
submitted in the normal procedure were omitted. RESULTS: Between 2005–2008 the 
total number of applications was 519, 440, 399, 377; while the average delay was 94, 
